C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models

Cheng Tang, Kimberly Gómez, Yan Chen, Heather N. Allen, Sara Hestehave, Erick J. Rodríguez‐Palma, Santiago Loya‐López, Aida Calderón‐Rivera, Paz Duran, Tyler S. Nelson, Raju S. Kanumuri, Bijal Shah, Nihar R. Panigrahi, Samantha Perez‐Miller, Morgan K. Schackmuth, Shivani Ruparel, Amol Patwardhan, Theodore J. Price, Paramjit S. Arora, Ravindra K. Sharma, Abhisheak Sharma, Jie Yu, Olga A. Korczeniewska, Rajesh KhannaJournal of Clinical Investigation 2024 · DOI

TL;DR

Researchers have identified a novel small molecule, C2230, that selectively blocks $Ca_V2.2$ (N-type) calcium channels—a validated but "difficult" target for chronic pain. Unlike existing treatments that cause severe side effects, C2230 is "use-dependent," meaning it primarily targets hyperactive neurons involved in pain while sparing normal motor and cardiovascular functions.

What Problem Does This Paper Address?

Chronic pain affects millions, yet our pharmacological toolkit is limited. Current $Ca_V2.2$ blockers like Ziconotide (Prialt) are highly effective but require invasive spinal injections because they don't cross the blood-brain barrier well, and they carry a heavy burden of side effects like dizziness and confusion. Other drugs, like Gabapentin, face issues with misuse and overdose.

The "holy grail" in this field is a small molecule that can be delivered easily (e.g., orally or intranasally) and selectively targets the "overactive" state of channels during chronic pain without interfering with the channels' normal physiological roles. This paper introduces C2230 as a promising candidate that meets these criteria.

Methods

The authors employed a multi-disciplinary approach to validate C2230:

  • High-Throughput Screening: They screened a library of over 4,200 small molecules using manual patch-clamp electrophysiology to find potent $Ca_V2.2$ antagonists.
  • Kinetic Analysis: Using patch-clamp on HEK293 cells, they characterized the "state-dependence" (whether it prefers open, closed, or inactivated channels) and "use-dependence" (whether it works better during high-frequency firing).
  • Cross-Species Validation: They tested the compound on primary sensory neurons (DRG and TG neurons) from rats, marmosets, and humans.
  • In Vivo Pain Models: They evaluated C2230 across four distinct pain models: neuropathic (nerve injury), orofacial (face pain), and osteoarthritic (joint pain).
  • Advanced Behavioral & Imaging Tech: They used fiber photometry to image calcium dynamics in the brain's parabrachial nucleus (a pain-processing hub) and Conditioned Place Aversion (CPA) to measure the emotional/aversive component of pain.
  • Site-Directed Mutagenesis: They systematically mutated the channel to map where C2230 binds.

Datasets

  • Compound Library: Selleck Chemicals LLC (Catalog No. L3600), containing 4,200+ structurally diverse small molecules.
  • Biological Samples: Primary neurons derived from Sprague-Dawley rats, Callithrix jacchus (marmoset), and human donors (via the Southwest Transplant Alliance).
  • Structural Data: Human $Ca_V2.2$ cryo-EM structures (PDB: 7VFV) were used for modeling and comparison.

Key Insights and Ideas

  • The "Smart" Blocker: C2230 is use-dependent. It binds more effectively when the channel is firing rapidly—a hallmark of pain signaling. This allows it to inhibit "pathological" activity while leaving "normal" activity relatively untouched.
  • State-Preference: It specifically stabilizes the inactivated state of the channel. By trapping the channel in its "off" position, it prevents the release of pain-signaling neurotransmitters like CGRP.
  • Broad Selectivity: While many blockers hit multiple calcium or sodium channels (leading to heart or motor issues), C2230 showed high selectivity for $Ca_V2.2$ over $Na_V1.5$ (heart) and $K_V$ channels.
  • Novel Binding Site: Mutagenesis revealed that C2230 does not bind in the traditional pore or the DIII/DIV fenestration used by other known blockers. This suggests a unique mechanism of action that could avoid the pitfalls of previous drug candidates.
  • Emotional Relief: Beyond just blocking the physical sensation of pain, fiber photometry and CPA assays showed that C2230 reduces the unpleasantness and brain-level activity associated with chronic injury.

Key Results

  • Potency: C2230 was ~8 times more potent at a depolarized (inactivated) state ($IC_{50}$ = 1.3 $\mu$M) than at a resting state ($IC_{50}$ = 10.2 $\mu$M).
  • Neurotransmitter Inhibition: It reduced the release of the pro-pain peptide iCGRP by approximately 51%.
  • In Vivo Efficacy: In mice with nerve injuries, C2230 dose-dependently reversed mechanical and cold hypersensitivity. The effective dose ($ED_{20}$) was roughly 4.9 mg/kg.
  • Safety Profile: Even at the highest doses tested (30 mg/kg), C2230 did not impair motor coordination (rotarod test) or affect blood pressure and heart rate—common failure points for N-type blockers.
  • No Tolerance: Unlike opioids, repeated administration over 9 weeks did not lead to a loss of efficacy.

Limitations and Future Work

  • Enantiomers: The study used a racemic mixture (a 50/50 mix of "left-handed" and "right-handed" molecules). The authors note that testing pure enantiomers might yield even higher potency or selectivity.
  • Binding Pocket: While they ruled out known binding sites, the exact structural pocket for C2230 remains to be fully resolved via high-resolution structural biology (like cryo-EM).
  • Clinical Translation: While the results in human neurons and marmosets are encouraging, moving from rodent models to human clinical trials is a notoriously difficult leap in pain research.

Reference: Tang, C., et al. (2025). C2230, a preferential use- and state-dependent $Ca_V2.2$ channel blocker, mitigates pain behaviors across multiple pain models. The Journal of Clinical Investigation.

Summary updated

Abstract

Antagonists - such as Ziconotide and Gabapentin - of the CaV2.2 (N-type) calcium channels are used clinically as analgesics for chronic pain. However, their use is limited by narrow therapeutic windows, difficult dosing routes (Ziconotide), misuse, and overdoses (Gabapentin), as well as a litany of adverse effects. Expansion of novel pain therapeutics may emerge from mechanism-based interrogation of CaV2.2. Here, we report the identification of C2230, an aryloxy-hydroxypropylamine, as a CaV2.2 blocker. C2230 trapped and stabilized inactivated CaV2.2 in a slow-recovering state and accelerated the open-state inactivation of the channel, conferring an advantageous use-dependent inhibition profile. C2230 inhibited CaV2.2 during high-frequency stimulation, while sparing other voltage-gated ion channels. C2230 inhibited CaV2.2 in dorsal root and trigeminal ganglia neurons from rats, marmosets, and humans in a G-protein-coupled-receptor-independent manner. Further, C2230 reduced evoked excitatory postsynaptic currents and excitatory neurotransmitter release in the spinal cord, leading to relief of neuropathic, orofacial, and osteoarthritic pain-like behaviors via 3 different routes of administration. C2230 also decreased fiber photometry-based calcium responses in the parabrachial nucleus, mitigated aversive behavioral responses to mechanical stimuli after neuropathic injury, and preserved protective pain responses, all without affecting motor or cardiovascular function. Finally, site-directed mutation analysis demonstrated that C2230 binds differently than other known CaV2.2 blockers, making it a promising lead compound for analgesic development.
BibTeX
@article{tang2024c,
  author = {Cheng Tang and Kimberly Gómez and Yan Chen and Heather N. Allen and Sara Hestehave and Erick J. Rodríguez‐Palma and Santiago Loya‐López and Aida Calderón‐Rivera and Paz Duran and Tyler S. Nelson and Raju S. Kanumuri and Bijal Shah and Nihar R. Panigrahi and Samantha Perez‐Miller and Morgan K. Schackmuth and Shivani Ruparel and Amol Patwardhan and Theodore J. Price and Paramjit S. Arora and Ravindra K. Sharma and Abhisheak Sharma and Jie Yu and Olga A. Korczeniewska and Rajesh Khanna},
  title = {{C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models}},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci177429},
}
Figure